Clostridium butyricum is a bacterium that produces a Type E botulinum toxin. This toxin is one of the seven types of botulinum toxins produced by Clostridium species, and is known for its ability to cause botulism, a rare but serious illness that can lead to paralysis, respiratory failure, and other life-threatening complications.

The Type E botulinum toxin produced by Clostridium butyricum is similar in structure and function to other botulinum toxins. It works by blocking the release of acetylcholine at neuromuscular junctions, which can cause muscle weakness and paralysis.

The symptoms of botulism caused by Clostridium butyricum Type E Botulinum Toxin can vary depending on the severity of the infection. In mild cases, symptoms may include muscle weakness, double vision, and difficulty speaking or swallowing. In more severe cases, the toxin can cause respiratory failure, which can be life-threatening.

There are a few different ways that people can become infected with Clostridium butyricum Type E Botulinum Toxin. One common source of infection is through the consumption of improperly canned or preserved foods, such as smoked fish or meat products. The bacteria can also be found in soil and water and can enter the body through wounds or other openings in the skin.

Preventing infection with Clostridium butyricum Type E Botulinum Toxin involves proper food handling and preparation, as well as avoiding contact with contaminated soil or water. Treatment for botulism caused by this toxin typically involves supportive care, such as mechanical ventilation to assist with breathing, and antitoxin therapy to neutralize the effects of the toxin.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, successful recombinant protein expression in heterologous expression systems depends on various factors, including codon preference, RNA secondary structure, and GC content. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins. Compared to pre-optimization, more experimental results demonstrated that the expression level was dramatically increased, ranging from two to a hundred times depending on the gene.

Clostridium butyricum cDNA and recombinant antigens can be used in a variety of applications to detect and diagnose Clostridium-related diseases. The cDNA and recombinant antigens can be used as probes for PCR or hybridization to detect the presence of Clostridium DNA in clinical specimens. The recombinant antigens can also be used as immunogens to generate antibodies that are useful for detecting Clostridium-related diseases. Furthermore, the cDNA and recombinant antigens can be used to develop vaccines to protect against Clostridium-related diseases.